🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06788418
Recruiting Not applicable

Comparative Study of SMILE, ICL, and Wavelight Plus Alcon Technologies in Myopia Correction

NCT06788418 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2025-01-20
Last updated
2025-01-23

Condition(s) studied

Myopia

Investigational drug(s) / intervention(s)

Wavelight Plus Alcon systemSMILEICL

Wavelight Plus Alcon system: Wavelight Plus Alcon system guided surgery for myopia

SMILE: Small Incision Lenticule Extraction surgery for myopia

ICL: Implantable Collamer Lens surgery for myopia

Study summary

Myopia is a prevalent refractive error with significant lifestyle impact. While traditional SMILE (Small Incision Lenticule Extraction) and ICL (Implantable Collamer Lens) surgeries are standard options, the advent of the Wavelight Plus Alcon system presents a promising new technique. This trial aims to evaluate the safety, efficacy, and patient satisfaction across these methods.

Eligibility

Sex
ALL
Min age
18 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18-40 years * Spherical equivalent of -1.00 to -10.00 D * Stable refraction for at least 12 months * Informed consent provided Exclusion Criteria: * Other ocular pathologies * Previous refractive surgery * Pregnancy or nursing * Autoimmune or connective tissue disorders

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Beijing New Vision Eye Hospital Beijing China Recruiting
Beijing Visionly Plus Eye Hospital Beijing China Recruiting

More Beijing Visionly Plus Eye Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06788418 on ClinicalTrials.gov ↗ ← All trials in China